Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619852 | 0.83 | LMNA (0.40) | LMNAALDH1A1USP2THRBCYP1A2 | |
| SCHEMBL285035 | 0.83 | THRB (0.52) | LMNAALDH1A1USP2THRBCYP1A2 | |
| SCHEMBL20646684 | 0.82 | USP2 (0.36) | LMNAALDH1A1USP2 | |
| SCHEMBL3739869 | 0.81 | USP2 (0.42) | LMNAALDH1A1USP2THRBCYP1A2 | |
| SCHEMBL1671352 | 0.81 | LMNA (0.38) | LMNAALDH1A1USP2THRBCYP1A2 | |
| SCHEMBL888322 | 0.81 | TSHR (0.43) | LMNAALDH1A1USP2THRBCYP1A2 | |
| SCHEMBL8991618 | 0.79 | — | — | |
| SCHEMBL15023217 | 0.78 | USP2 (0.35) | LMNAALDH1A1USP2CYP1A2KDM4E | |
| SCHEMBL1206579 | 0.78 | USP2 (0.44) | LMNAALDH1A1USP2THRBCYP1A2 | |
| SCHEMBL28951126 | 0.78 | ALDH1A1 (0.35) | LMNAALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288230-A1 | METHOD FOR PREPARING POLYHYDROXY-URETHANES | RHODIA OPERATIONS (FR) | 2011-11-24 | — | — | US | claimed |
| CN-105431139-B | For carrying out the stereospecificity lipid of local treatment with the stimulation-sensibility nano-carrier system recycled for a long time | 特默佐梅有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-105431139-A | Stereospecific lipids for locoregional therapy with long-term circulating stimuli-sensitive nanocarrier systems | THERMOSOME GmbH | 2016-03-23 | — | — | CN | disclosed |
| EP-2262752-B1 | IMPROVED HYDROGENATION PROCESS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8324434-B2 | Hydrogenation process | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110288230-A1 | METHOD FOR PREPARING POLYHYDROXY-URETHANES | RHODIA OPERATIONS (FR) | 2011-11-24 | — | — | US | disclosed |
| US-8017719-B2 | Method for preparing polyhydroxy-urethanes | RHODIA OPERATIONS (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20110060168-A1 | IMPROVED HYDROGENATION PROCESS | DOW GLOBAL TECHNOLOGIES LLC | 2011-03-10 | — | — | US | disclosed |
| EP-2262752-A1 | IMPROVED HYDROGENATION PROCESS | Dow Global Technologies Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111352-A1 | IMPROVED HYDROGENATION PROCESS | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-0423266-A4 | METHOD AND COMPOSITION FOR TREATMENT OF PERIODONTAL DISEASE | — | 1991-09-25 | — | — | EP | disclosed |
| EP-0423266-A1 | METHOD AND COMPOSITION FOR TREATMENT OF PERIODONTAL DISEASE | BENHURI, Marc N (US) | 1991-04-24 | — | — | EP | disclosed |
| WO-1990009779-A1 | METHOD AND COMPOSITION FOR TREATMENT OF PERIODONTAL DISEASE | BENHURI MARC N (US) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288230-A1 | METHOD FOR PREPARING POLYHYDROXY-URETHANES | UROD, HPD, ALKBH3 | LMNA 2578/4885ALDH1A1 2408/4885USP2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.